-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bullous pemphigoid is a difficult-to-treat autoimmune bullous skin disease that primarily affects older adults and is associated with increased mortali.
This multicenter, single-arm, phase 2a non-randomized controlled trial was conducted at university dermatology departments in the Netherlands and Germa.
RESULTS: A total of 9 patients with bullous pemphigoid (median [range] age, 75 [55-85] years) were included in the trial, 5 of whom were women (56.
Taken together, the results of this non-randomized controlled trial suggest that Nomacopan is well tolerated in elderly patients with bullous pemphigoid and may have a therapeutic effect in suppressing the exacerbation of this disea.
Original source:
Christian D Sadik, et .
leave a message here